UNI-MB - logo
UMNIK - logo
 

Rezultati iskanja

Osnovno iskanje    Izbirno iskanje   
Iskalna
zahteva
Knjižnica

Trenutno NISTE avtorizirani za dostop do e-virov UM. Za polni dostop se PRIJAVITE.

1 2 3 4 5
zadetkov: 63.406
1.
  • First-Line Immunotherapy for Non-Small-Cell Lung Cancer
    Reck, Martin; Remon, Jordi; Hellmann, Matthew D Journal of clinical oncology, 02/2022, Letnik: 40, Številka: 6
    Journal Article
    Recenzirano

    For patients with metastatic non-small-cell lung cancer (mNSCLC), the last decade has been characterized by critical progress that has contributed to substantially improved survival. In particular, ...
Celotno besedilo
2.
  • Adjuvant chemotherapy for r... Adjuvant chemotherapy for resected early‐stage non‐small cell lung cancer
    Burdett, Sarah; Pignon, Jean Pierre; Tierney, Jayne ... Cochrane database of systematic reviews, 03/2015, Letnik: 2015, Številka: 3
    Journal Article
    Recenzirano
    Odprti dostop

    Background To evaluate the effects of administering chemotherapy following surgery, or following surgery plus radiotherapy (known as adjuvant chemotherapy) in patients with early stage non‐small cell ...
Celotno besedilo

PDF
3.
  • Lung cancer: current therap... Lung cancer: current therapies and new targeted treatments
    Hirsch, Fred R, Prof; Scagliotti, Giorgio V, Prof; Mulshine, James L, Prof ... Lancet, 01/2017, Letnik: 389, Številka: 10066
    Journal Article
    Recenzirano
    Odprti dostop

    Summary Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6 million people die as a result of the ...
Celotno besedilo

PDF
4.
  • The biology and management of non-small cell lung cancer
    Herbst, Roy S; Morgensztern, Daniel; Boshoff, Chris Nature (London), 01/2018, Letnik: 553, Številka: 7689
    Journal Article
    Recenzirano

    Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of ...
Celotno besedilo
5.
  • Five-Year Outcomes From the... Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer
    Borghaei, Hossein; Gettinger, Scott; Vokes, Everett E ... Journal of clinical oncology, 03/2021, Letnik: 39, Številka: 7
    Journal Article
    Recenzirano
    Odprti dostop

    Immunotherapy has revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in overall ...
Celotno besedilo

PDF
6.
  • Osimertinib in Resected EGFR -Mutated Non-Small-Cell Lung Cancer
    Wu, Yi-Long; Tsuboi, Masahiro; He, Jie ... The New England journal of medicine, 10/2020, Letnik: 383, Številka: 18
    Journal Article
    Recenzirano

    Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor ( ) mutation-positive advanced non-small-cell lung cancer (NSCLC). The efficacy and safety of ...
Preverite dostopnost


PDF
7.
  • Nivolumab plus Ipilimumab i... Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
    Hellmann, Matthew D; Paz-Ares, Luis; Bernabe Caro, Reyes ... New England journal of medicine/˜The œNew England journal of medicine, 11/2019, Letnik: 381, Številka: 21
    Journal Article
    Recenzirano
    Odprti dostop

    In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly ...
Celotno besedilo

PDF
8.
  • Atezolizumab for First-Line... Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
    Herbst, Roy S; Giaccone, Giuseppe; de Marinis, Filippo ... New England journal of medicine/˜The œNew England journal of medicine, 10/2020, Letnik: 383, Številka: 14
    Journal Article
    Recenzirano
    Odprti dostop

    The efficacy and safety of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients ...
Celotno besedilo

PDF
9.
  • Afatinib versus cisplatin p... Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
    Wu, Yi-Long, Prof; Zhou, Caicun, Prof; Hu, Cheng-Ping, Prof ... The lancet oncology, 02/2014, Letnik: 15, Številka: 2
    Journal Article
    Recenzirano

    Summary Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR ...
Celotno besedilo
10.
  • Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
    Tsuboi, Masahiro; Herbst, Roy S; John, Thomas ... The New England journal of medicine, 07/2023, Letnik: 389, Številka: 2
    Journal Article
    Recenzirano

    Among patients with resected, epidermal growth factor receptor ( )-mutated, stage IB to IIIA non-small-cell lung cancer (NSCLC), adjuvant osimertinib therapy, with or without previous adjuvant ...
Preverite dostopnost
1 2 3 4 5
zadetkov: 63.406

Nalaganje filtrov